Neurocrine(US:NBIX) Prnewswire·2025-10-06 12:30Core Insights - Neurocrine Biosciences presented new data from the KINECT-HD2 study, showing long-term safety, tolerability, and sustained improvements in chorea severity with once-daily INGREZZA (valbenazine) in adults with Huntington's disease [1][2] Study Findings - The KINECT-HD2 study involved 154 adult participants treated with INGREZZA for up to three years, demonstrating early and sustained improvements in chorea severity [2][7] - Improvements in the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) score were observed as early as Week 2, with a mean improvement of -3.4±0.3 at the lowest dose of 40 mg [5] - By Week 156, 77.8% of participants reported a "much improved" status on the Patient Global Impression of Change (PGI-C) score [5] Safety and Tolerability - INGREZZA was generally well tolerated, with treatment-emergent adverse events (TEAEs) consistent with its established safety profile [3][5] - The most common TEAEs included falls (42.9%), somnolence (25.3%), and fatigue (21.4%), with serious TEAEs occurring in less than 2% of participants [5] Efficacy Analysis - The study indicated that concomitant antipsychotic use had no effect on chorea improvement, suggesting that INGREZZA can be used alongside other medications without compromising efficacy [2][5] - Efficacy was maintained throughout the treatment period, with significant improvements noted at various time points from Week 2 to Week 156 [5] About INGREZZA - INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treating chorea associated with Huntington's disease and tardive dyskinesia [7][8] - The drug is available in 40 mg, 60 mg, and 80 mg capsules, and offers a sprinkle formulation for patients with swallowing difficulties [9]